-

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Focus Financial Partners Inc. Stockholder Buyout and Encourages Investors to Contact the Firm – FOCS

PHILADELPHIA--(BUSINESS WIRE)--Investor protection law firm Kaskela Law LLC announces that it is investigating the proposed stockholder buyout of Focus Financial Partners Inc. (“Focus” or the “Company”) (NASDAQ: FOCS) on behalf of the Company’s shareholders.

On February 27, 2023, Focus announced that it would be acquired by private investment firms Clayton, Dubilier & Rice, LLC (“CDR”) and Stone Point Capital LLC (“Stone Point”) at a price of $53.00 per share in cash. Following the closing of the proposed transaction, Focus investors will be cashed out of their investment position and the Company’s shares will no longer be publicly traded.

The investigation seeks to determine whether Focus investors will be receiving sufficient payment for their FOCS shares, as the proposed $53.00 per share buyout price is less than a 10% premium to Focus’ closing price of $50.20 per share on the prior trading day, and is significantly lower than Focus’ closing price of over $68.00 per share in November 2021.

Focus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (skaskela@kaskelalaw.com or abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/focus-financial-partners/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

Contacts

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
(888) 715 – 1740
www.kaskelalaw.com

Kaskela Law LLC

NASDAQ:FOCS

Release Versions

Contacts

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
(888) 715 – 1740
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law LLC Announces Investigation into Fairness of $9.50 Per Share Global Business Travel Group (GBTG) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Kaskela Law is investigating the fairness of the recently announced buyout of Global Business Travel Group, Inc. (NYSE: GBTG) (“GBTG”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their GBTG shares. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/global-business-travel-group/ On May 4, 2026, GBTG announced that it had agreed to go privat...

Kaskela Law LLC Announces Shareholder Investigation of Playtika Holding Corp. and Encourages Investors with Losses to Contact the Firm – PLTK

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Shareholder litigation law firm Kaskela Law is investigating Playtika Holding Corp. (NASDAQ: PLTK) (“Playtika”) on behalf of the company’s investors. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/playtika-holding/ Since July 2025, shares of Playtika’s common stock have declined in value from a trading price of over $4.50 per share to a current price of less than $3.50 per share, a decline of over 22%...

Kaskela Law LLC Announces Investigation into Fairness of $16.50 Per Share Select Medical Holdings (SEM) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Shareholder litigation law firm Kaskela Law is investigating the fairness of the recently announced buyout of Select Medical Holdings Corp. (NYSE: SEM) (“Select Medical”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their shares. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/select-medical/ On March 2, 2026, Select Medical announced th...
Back to Newsroom